Skip to main content
. Author manuscript; available in PMC: 2022 Jan 25.
Published in final edited form as: Int J Pharm. 2020 Dec 2;593:120121. doi: 10.1016/j.ijpharm.2020.120121

Figure 8.

Figure 8

Mass distribution of the inhalable vaccine powder for each formulation. Depth of penetration varied based on formulation composition. The trileucine-containing formulations had the greatest penetration, with deposition measured on the micro-orifice collector (MOC) of the impactor. Results shown represent the average of triplicate measurements and error bars represent standard deviation.